147 related articles for article (PubMed ID: 16322899)
21. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Miller WR; Larionov A
Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
Tabchy A; Valero V; Vidaurre T; Lluch A; Gomez H; Martin M; Qi Y; Barajas-Figueroa LJ; Souchon E; Coutant C; Doimi FD; Ibrahim NK; Gong Y; Hortobagyi GN; Hess KR; Symmans WF; Pusztai L
Clin Cancer Res; 2010 Nov; 16(21):5351-61. PubMed ID: 20829329
[TBL] [Abstract][Full Text] [Related]
23. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
Iwamoto T; Bianchini G; Booser D; Qi Y; Coutant C; Shiang CY; Santarpia L; Matsuoka J; Hortobagyi GN; Symmans WF; Holmes FA; O'Shaughnessy J; Hellerstedt B; Pippen J; Andre F; Simon R; Pusztai L
J Natl Cancer Inst; 2011 Feb; 103(3):264-72. PubMed ID: 21191116
[TBL] [Abstract][Full Text] [Related]
24. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
25. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy.
Chen Y; Chen C; Yang B; Xu Q; Wu F; Liu F; Ye X; Meng X; Mougin B; Liu G; Shen Z; Shao Z; Wu J
Cancer Lett; 2011 Mar; 302(1):63-8. PubMed ID: 21220187
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Schneeweiss A; Lauschner I; Ruiz A; Guerrero A; Sánchez-Rovira P; Seguí MA; Goerke K; Wolf M; Manikhas AG; Wacker J; Marmé F; Lichter P; Sinn HP; Sohn C; Mansouri K; Bauknecht T; Hahn M
Clin Breast Cancer; 2007 Apr; 7(7):555-8. PubMed ID: 17509164
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
Jeong JH; Jung SY; Park IH; Lee KS; Kang HS; Kim SW; Kwon Y; Kim EA; Ko KL; Nam BH; Lee S; Ro J
Invest New Drugs; 2012 Feb; 30(1):408-16. PubMed ID: 20922557
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.
Saura C; Tseng LM; Chan S; Chacko RT; Campone M; Manikhas A; Nag SM; Leichman CG; Dasappa L; Fasching PA; Hurtado de Mendoza F; Symmans WF; Liu D; Mukhopadhyay P; Horak C; Xing G; Pusztai L
Oncologist; 2013; 18(7):787-94. PubMed ID: 23853246
[TBL] [Abstract][Full Text] [Related]
30. High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer.
Wang Y; Sparano JA; Fineberg S; Stead L; Sunkara J; Horwitz SB; McDaid HM
Clin Breast Cancer; 2013 Apr; 13(2):103-8. PubMed ID: 23218766
[TBL] [Abstract][Full Text] [Related]
31. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
Learn PA; Yeh IT; McNutt M; Chisholm GB; Pollock BH; Rousseau DL; Sharkey FE; Cruz AB; Kahlenberg MS
Cancer; 2005 Jun; 103(11):2252-60. PubMed ID: 15834928
[TBL] [Abstract][Full Text] [Related]
32. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
Evans TR; Yellowlees A; Foster E; Earl H; Cameron DA; Hutcheon AW; Coleman RE; Perren T; Gallagher CJ; Quigley M; Crown J; Jones AL; Highley M; Leonard RC; Mansi JL
J Clin Oncol; 2005 May; 23(13):2988-95. PubMed ID: 15860854
[TBL] [Abstract][Full Text] [Related]
33. A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study.
Antolín S; Mel R; Ramos M; García-Palomo A; Almanza C; de Paz L; Calvo L; Alvarez E; González A; García-Mata J
Clin Transl Oncol; 2011 Sep; 13(9):686-91. PubMed ID: 21865141
[TBL] [Abstract][Full Text] [Related]
34. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.
Litviakov NV; Cherdyntseva NV; Tsyganov MM; Slonimskaya EM; Ibragimova MK; Kazantseva PV; Kzhyshkowska J; Choinzonov EL
Oncotarget; 2016 Feb; 7(7):7829-41. PubMed ID: 26799285
[TBL] [Abstract][Full Text] [Related]
35. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
Xing AY; Wang B; Li YH; Chen X; Wang YW; Liu HT; Gao P
Pathol Oncol Res; 2021; 27():1609753. PubMed ID: 34257614
[No Abstract] [Full Text] [Related]
36. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Perez EA; Geeraerts L; Suman VJ; Adjei AA; Baron AT; Hatfield AK; Maihle N; Michalak JC; Kuross SA; Kugler JW; Lafky JM; Ingle JN
Ann Oncol; 2002 Aug; 13(8):1225-35. PubMed ID: 12181246
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
Ayers M; Symmans WF; Stec J; Damokosh AI; Clark E; Hess K; Lecocke M; Metivier J; Booser D; Ibrahim N; Valero V; Royce M; Arun B; Whitman G; Ross J; Sneige N; Hortobagyi GN; Pusztai L
J Clin Oncol; 2004 Jun; 22(12):2284-93. PubMed ID: 15136595
[TBL] [Abstract][Full Text] [Related]
38. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
Sparano JA; Moulder S; Kazi A; Coppola D; Negassa A; Vahdat L; Li T; Pellegrino C; Fineberg S; Munster P; Malafa M; Lee D; Hoschander S; Hopkins U; Hershman D; Wright JJ; Kleer C; Merajver S; Sebti SM
Clin Cancer Res; 2009 Apr; 15(8):2942-8. PubMed ID: 19351752
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]